About Eribulin Mesylate
            
            Class: | Antineoplastic agent, Microtubule inhibitor  
Use: | Treatment of metastatic breast cancer in patients who have received at least two prior therapies for metastatic disease, including an anthracycline and a taxane. Also indicated for the treatment of liposarcoma after prior therapies.  
Adult dose: | 1.4 mg/m² administered intravenously over 2 to 5 minutes on days 1 and 8 of a 21-day cycle.  
Pediatric dose: | Safety and efficacy have not been established in pediatric patients; not reco
         
        
            
                
                
                    
                        Drug Class
                    
                    Antineoplastic agent, Microtubule inhibitor
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of metastatic breast cancer in patients who have received at least two prior therapies for metastatic disease, including an anthracycline and a taxane. Also indicated for the treatment of liposarcoma after prior therapies.
                 
                
                
                    
                        Storage Requirements
                    
                    Store at 20°C to 25°C (68°F to 77°F); protect from light; do not freeze. Once diluted, the solution should be used immediately or stored at 2°C to 8°C (36°F to 46°F) for up to 24 hours.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Eisai Europe Limited, UNITED KINGDOM
                    
                    
                    Package Size
                    2ml Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 2416.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        1.4 mg/m² administered intravenously over 2 to 5 minutes on days 1 and 8 of a 21-day cycle.
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy have not been established in pediatric patients; not recommended for use in this population.
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include fatigue, nausea, neutropenia, peripheral neuropathy, alopecia, constipation, and diarrhea.
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to eribulin or any component of the formulation; patients with severe liver impairment (Child-Pugh Class C).
         
        
        
            
                Important Warnings
            
            Risk of myelosuppression, including neutropenia; monitor complete blood counts regularly. Risk of peripheral neuropathy; assess for symptoms prior to each dose. Use caution in patients with hepatic impairment.
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.